Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® Cutaneous Melanoma Guidelines to Assess Metastatic Risk

SkylineDx United States of America Netherlands

Merlin CP-GEP is the only molecular test recognized by NCCN as predictive and appropriate for use in select T1 and T2 patients to support shared decision-making regarding Sentinel Lymph Node Biopsy.NCCN guidelines highlight that patients identified as Merlin High Risk may have a threefold increased risk of sentinel lymph node (SLN) involvement based on recently published data from the largest prospective, blinded trial for a molecular test in cutaneous melanoma.View original content:https://www.prnewswire.co.uk/news-releases/merlin-cp-gep-becomes-the-first-and-only-gene-expression-profile-gep-test-recommended-by-nccn-cutaneous-melanoma-guidelines-to-assess-metastatic-risk-302692474.html